Heartware Annual General Meeting Presentation May 23, 2006

Sydney, May 23, 2006 AEST (ABN Newswire) - HeartWare (ASX: HTW) in accordance with ASX Listing Rule 3.13.3 provides a copy of the presentations which are to be delivered today at the Company's Annual General Meeting.

Overview:
Heart failure is a leading cause of death in the developed world and represents a significant emerging medical device market

- HeartWare is developing a family of implantable heart pumps for the treatment of advanced heart failure

- HeartWare's HVAD, the smallest 3rd generation heart pump, is demonstrating outstanding early clinical results

- By the end of 2006, HeartWare aims to complete enrolment in its EU / Australian clinical trial and to commence its US clinical trials, subject to approvals

- HeartWare's next generation device, the MVAD, is in pre-clinical studies

- HeartWare has a strong IP portfolio and proven management capability


The Presentation is available for download at;
http://htw.irmau.com/irm/Company/ShowPage.aspx?CPID=1005

The AGM is being held at the Company's auditors, Grant Thornton, at Level 17, 383 Kent Street, Sydney, commencing at 10am.

The AGM may also be viewed by webcast at the following address:
http://www.streamx.com.au/heartware/agm06/start.htm

Source:
HeartWare Limited Investment Centre